Ogeda (Belgium)

Recent papers from Ogeda (Belgium)

1. Clinical Pharmacokinetics, Mass Balance and Metabolism of Fezolinetant in Postmenopausal WomenEuropean Journal of Drug Metabolism and Pharmacokinetics · 2026
2. Concentration–QTc Modeling to Support Clinical Development of FezolinetantClinical Pharmacology in Drug Development · 2025
3. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism · 2021
4. Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin CarcinogenesisFrontiers in Oncology · 2019
5. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a TrialThe Journal of Clinical Endocrinology & Metabolism · 2019
6. Fatty-Acid Binding Protein 4 (FABP4) as a Potential Preclinical Biomarker of Drug-Induced Kidney InjuryToxicological Sciences · 2018
7. A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epitheliaScience Signaling · 2017